Radiation Therapy Prostate Cancer VMAT IMRT

February 12, 2013 — According to a clinical study in the January issue of the Journal of the American College of Radiology, the use of volume-modulated arc therapy (VMAT) to deliver intensity-modulated radiation therapy (IMRT) to prostate cancer patients results in an overall reduction in treatment time of approximately 14 percent.

Treatment with IMRT is increasingly standard for prostate cancer. However, although the benefits of IMRT in the treatment of prostate cancer are ample, it remains a complex and time-consuming treatment modality that requires numerous gantry positions, a large number of monitor units and considerable daily treatment time commitments by patients.

“Given the time requirement by patients for daily prostate cancer treatment, we aimed to measure the true efficiency of VMAT treatment compared with IMRT using custom institutional software to record the actual in-room times,” said William A. Hall, M.D., author of the study.

Custom institutional software was used to mine the treatment times from the record-and-verify database. The in-room time (the time between patient entry and exit) was computed for each patient. Average room time was compared between VMAT patients and IMRT patients. Subgroup comparisons (1-arc or 2-arc VMAT, 5-field or 7-field IMRT, and electromagnetic transponder [Calypso] or gold-marker tracking) were performed.

Average room time was significantly shorter for all VMAT versus DMLC IMRT procedures. The average room time for all DMLC IMRT patients was found to be 14.69 ± 4.36 min, and the average room time for all VMAT patients was found to be 12.6 ± 2.62 min. Room time was longer for Calypso versus gold seed patients, but VMAT reduced treatment time in Calypso patients. This resulted in Calypso VMAT patients’ having similar treatment times to non-Calypso DMLC IMRT patients.

“With an aging population and rapidly rising rates of prostate cancer, the ability to determine the most efficient modality by which patients with adenocarcinoma of the prostate should be treated is critical. It seems from our analysis that 5-field IMRT and VMAT are the most efficient modalities by which to deliver prostate IMRT,” said Hall. 

“Furthermore, our analysis shows that if more advanced methods of IMRT delivery are used, localization devices can be incorporated without any statistically significant differences in the overall treatment time. This may provide important information to prostate cancer practices looking to improve their efficiency while maximizing the quality of their radiation therapy delivery,” said Hall.

For more information: www.acr.org


Related Content

News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Focused Ultrasound Therapy

Aug. 26, 2025 — In a quest for ever-more-effective treatments for pancreatic cancer, HonorHealth Research Institute is ...

Time August 29, 2025
arrow
Feature

A new study published in JCO Clinical Cancer Informatics tackles a critical challenge in cancer diagnostics: ensuring ...

Time July 01, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
Subscribe Now